Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,167
  • Shares Outstanding, K 7,210
  • Annual Sales, $ 128,940 K
  • Annual Income, $ -85,400 K
  • EBIT $ 26 M
  • EBITDA $ 31 M
  • 60-Month Beta -0.41
  • Price/Sales 0.36
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.68
  • Number of Estimates 1
  • High Estimate -0.68
  • Low Estimate -0.68
  • Prior Year -1.19
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.20 +18.81%
on 01/21/26
19.15 -73.94%
on 01/05/26
-12.87 (-72.06%)
since 12/22/25
3-Month
4.20 +18.81%
on 01/21/26
19.15 -73.94%
on 01/05/26
-9.64 (-65.89%)
since 10/22/25
52-Week
4.20 +18.81%
on 01/21/26
19.15 -73.94%
on 01/05/26
-1.90 (-27.58%)
since 01/22/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA).  Such investors are...

ATRA : 5.02 (+9.13%)
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOâ„¢ (tabelecleucel)

U.S. Food and Drug Administration has issued a Complete Response Letter (CRL)

ATRA : 5.02 (+9.13%)
Atara Biotherapeutics: Q3 Earnings Snapshot

Atara Biotherapeutics: Q3 Earnings Snapshot

ATRA : 5.02 (+9.13%)
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including...

ATRA : 5.02 (+9.13%)
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDUFA)...

ATRA : 5.02 (+9.13%)
5 Under-the-Radar Biotech Stocks That Could Soar in 2026

These smaller innovators are quietly advancing promising therapies that could unlock their true potential.

SLN : 5.58 (-1.76%)
CRDL : 1.0380 (+1.76%)
TERN : 36.35 (-0.85%)
INO : 1.5400 (+1.99%)
TARA : 6.07 (+5.20%)
ATRA : 5.02 (+9.13%)
Atara Biotherapeutics Announces Significant Workforce Reduction

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

ATRA : 5.02 (+9.13%)
Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 5.02 (+9.13%)
Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Biotherapeutics: Q2 Earnings Snapshot

ATRA : 5.02 (+9.13%)
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has transferred substantially all operational...

ATRA : 5.02 (+9.13%)

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 5.28
2nd Resistance Point 4.99
1st Resistance Point 4.79
Last Price 5.02
1st Support Level 4.30
2nd Support Level 4.01
3rd Support Level 3.81

See More

52-Week High 19.15
Fibonacci 61.8% 13.44
Fibonacci 50% 11.67
Fibonacci 38.2% 9.91
Last Price 5.02
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar